Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2025.Dec.09

Announcement on behalf of Amaran the resignation of director

2025.Dec.09

Announcement on behalf of Amaran the retirement of Chairperson of the Board and General Manager

2025.Dec.05

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of gastric cancer

2025.Nov.24

Announcement of the Company’s record date of capital reduction, record date of share replacement, and related operational plan

2025.Nov.16

OBI receives US FDA Orphan Drug Designation for OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma

2025.Nov.14

OBI is invited to present the current development status of its products and technology platforms at the investor conference hosted by MasterLink

2025.Nov.10

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officers

2025.Nov.10

Announcement that the cumulative reduction of shareholding in major subsidiary, OBIGEN Pharma, has reached more than 10%

2025.Nov.10

Announcement of Change in the Company’s Certified Public Accountant Due to Internal Adjustment of the Accounting Firm

2025.Nov.10

Announcement of the Consolidated Financial Statements for the third quarter of 2025 were approved by the Board of Directors

News

Latest News

Events

Latest events